PRA Isoforms Are Targeted to Distinct Membrane Compartments*

Mohammad Abdul-Ghani, Pierre-Yves Gougeon, Derek C. Prosser, Lance F. Da-Silva, and Johnny K. NgseeDagger

From the Loeb Health Research Institute, University of Ottawa, 725 Parkdale Avenue, Ottawa, Ontario, K1Y 4E9 Canada

Received for publication, October 4, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The prenylated Rab acceptor (PRA) 1 is a protein that binds prenylated Rab GTPases and inhibits their removal from the membrane by GDI. We describe here the isolation of a second isoform that can also bind Rab GTPases in a guanine nucleotide-independent manner. The two PRA isoforms showed distinct intracellular localization with PRA1 localized primarily to the Golgi complex and PRA2 to the endoplasmic reticulum (ER) compartment. The localization signal was mapped to the COOH-terminal domain of the two proteins. A DXEE motif served to target PRA1 to the Golgi. Mutation of any one of the acidic residues within this motif resulted in significant retention of PRA1 in the ER compartment. Moreover, the introduction of a di-acidic motif to the COOH-terminal domain of PRA2 resulted in partial localization to the Golgi complex. The domain responsible for ER localization of PRA2 was also confined to the carboxyl terminus. Our results showed that these sorting signals were primarily responsible for the differential localization of the two PRA isoforms.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Rab GTPases are a family of 20-29-kDa Ras-like GTPases localized to unique intracellular organelles (1-7). They cycle through an active membrane-bound GTP- and inactive cytosolic GDP-bound states. They contain a characteristic Cys-containing motif at the extreme carboxyl terminus that is post-translationally modified by one or more prenyl residues (8-13). This modification is essential for membrane localization and function. The GDP-bound Rab is removed from the membrane by a cytosolic carrier protein known as GDI or GDP dissociation inhibitor, which also inhibits the dissociation of GDP and maintains Rab in the inactive state. Guanine nucleotide exchange occurs at the membrane and is catalyzed by a guanine nucleotide exchange factor of which a Rab3-specific (14) and the yeast Sec4p-specific form have been identified (15, 16). The low intrinsic GTPase activity requires catalysis by a GTPase activating protein of which a Rab3A-specific (17) and yeast Ypt-specific (18, 19) forms have been identified.

In ER1 to Golgi membrane trafficking, donor vesicles are tethered to the acceptor membrane compartment prior to SNARE-mediated fusion (20-23). Rab has been shown to mediate the recruitment of a cytosolic tethering protein, Uso1p, to the membranes. Another large protein complex called TRAPP may also be involved in this transport step (24). Tethering factors have been identified in other transport steps, suggesting conservation of this basic underlying process (25-27). Once docked, however, vesicle fusion is no longer dependent on Rab, but requires the SNARE proteins. Thus, stability of docked vesicles may represent a number of distinct molecular states: from molecular interactions that merely hold the two membranes in close proximity to those needed to trigger bilayer fusion. Studies on synaptic vesicles have shown that docked vesicles will undock about once every 2 min, a rate that is faster than spontaneous fusion (28). Thus, reversibility of vesicle tethering and docking provides a time constraint on subsequent steps.

Little is known on the mechanism of Rab localization to a specific membrane compartment. We have recently isolated a Rab-interacting protein called prenylated Rab acceptor or PRA1 (29). PRA1 interacts with both Rab and VAMP2 but not as a stable trimeric complex. In fact, binding of PRA1 to VAMP2 can be displaced by Rab3A, suggesting that PRA1 participates in the sequential assembly of protein by associating and dissociating from the Rab and VAMP2. Moreover, PRA1 inhibits the removal of Rab from the membrane by GDI (30). Thus, the recycling of Rab depends on the opposing action of PRA1 and GDI, with PRA1 favoring membrane retention and GDI favoring solubilization in the cytosol.

The existence of multiple isoforms seems to be a common theme in proteins involved in the various vesicle transport steps. Multiple isoforms of VAMP and syntaxin supports the concept that distinct members mediate specific membrane trafficking steps (31-33). We describe here the isolation of a second PRA isoform that shares many similarities to PRA1 including overall physical properties, tissue distribution, and broad binding specificity toward the Rab GTPases. However, it differs from PRA1 in its subcellular localization. Whereas PRA1 was localized predominantly in the Golgi complex, PRA2 was found in the ER compartment. Moreover, we showed that the localization signal resides in the COOH-terminal region of the proteins.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of PRA2-- A EST data base search using the conserved domain of the rat PRA1 resulted in a number of similar clones, most notably that with accession numbers AW519501 and AA051031. The rat PRA2 was subcloned into a vector containing the hemagglutinin (HA) tag by ligation between the StuI and XbaI sites. PRA2 was PCR-amplified from a rat brain cDNA library using the following oligonucleotides: 5'-TAAGGCCTATGGACGTGAACCTCG-3' and 5'-GCTCTAGATTACTCCCTCGCTTTGCTGA-3'. The resulting PCR fragment was sequenced.

Northern Blot Analysis-- A 32P-labeled full-length PRA2 probe was prepared using random hexamer labeling (Life Technologies). A multiple tissue blot (CLONTECH) containing poly(A)+-selected mRNA of various rat tissues was hybridized with 1 × 106 cpm/ml of 32P-labeled PRA2 in 10 ml of hybridization solution (5 × SSPE, 10 × Denhardt's solution, 100 µg/ml sheared salmon sperm DNA, 50% formamide, and 0.4% SDS) at 42 °C overnight.

Plasmid Construction-- PRA2 was subcloned into the yeast two-hybrid prey vector, pGAD424X using PRA2.E, 5'-CGAGAATTCTTACTCCCTGGCTTTGCTGAT-3' and PRA2.X2, 5'-GCCTCGAGTTACTCCCTSGCTTTGCTGA-3'. The VAMP1, VAMP2, and VAMP3 bait plasmids were described previously (29).

The HA-tagged PRA2 was subcloned into pQE10 (Qiagen) between the BamHI and the HindIII sites after PCR amplification using the following oligonucleotides: 5'-GCGGATCCTATGTACCCATACGATG-3' and 5'-GACAAGCTTACTCCCTGGCTTTGC-3'. The 6xHis-tagged PRA2 was purified the same way as the PRA1 using Ni-NTA resin as described (29).

The Rab GTPases were also subcloned into the 6xHis-tagged pQE41 (Qiagen) between the BamHI and SphI sites. Rab1A was PCR-amplified using the following oligonucleotides: 5'-TGTGGATCCATGTCCAGCATGAATCCCGAA-3' and 5'-CTAGGCATGCTTAGCAGCAGCCTCCACCTG-3'. The 6xHis-tagged Rab1A fragment was ligated into pYES2 (Invitrogen) between the EcoRI and SphI sites. The plasmid was then transformed into the yeast INVSc1 strain with Li acetate (34). To purify the 6xHis-tagged Rab1A, the transformed yeast was grown to saturation in 500 ml of Ura dropout medium. The cells were harvested at 3,000 × g for 5 min, transferred to 1 liter of YPG (containing 2% galactose and 1% raffinose instead of glucose), and grown at 30 °C for 8 h. The Rab1A was then purified from the yeast as described previously for Rab3A (30), except that phosphate-buffered saline was used instead of Tris-HCl and the proteins were eluted from the resin with 50 mM EDTA. The purified Rab3A and Rab1A were cross-linked to CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech AB) as described by the manufacturer.

Various domains of HA-tagged wild-type PRA1 and PRA2 were PCR amplified using pIRES/HA-PRA1 and pIRES/HA-PRA2 as DNA templates. Two rounds of PCR were used to generate the chimeras. The first round of PCR generated the individual PRA1 or PRA2 fragments, which served as templates for the second round to create the different chimeras. The PCR products were digested with ClaI and EcoRI and subcloned into the same restriction sites of the mammalian expression vector pIRESpuro (CLONTECH). The carboxyl regions of both PRA1 and PRA2 were PCR-amplified using the Bluescript KSII(-)/HA-PRA1 and KSII(-)/HA-PRA2 as DNA templates. PCR products were gel purified and subcloned into the GFP-containing vector, pEGFP-C1 (CLONTECH) as XhoI and BamHI fragments such that the GFP was fused to the amino terminus of the PCR product. All plasmids were sequenced to confirm the expected mutations.

Rab Binding Assay-- The binding of Rab1A and Rab3A to PRA1 and PRA2, in the presence of GDPbeta S or GTPgamma S was done using purified yeast or bacterially expressed proteins in a pull-down assay. A typical binding assay contained 20 µl of 50% bead slurry cross-linked with Rab1A or Rab3A at 2 pmol/µl. This was incubated for 1 h at 4 °C with 10, 15, and 20 pmol of recombinant PRA1 or PRA2 in a total volume of 250 µl of 25 mM Tris-HCl, pH 7.5, 125 mM KCl, 0.005% Triton X-100, 10% glycerol, 0.5 mM MgCl2, and 250 µM GDPbeta S or GTPgamma S (Roche Molecular Biochemicals). Controls were also done using Sepharose beads with no cross-linked Rab. The beads were then washed three times with 1 ml of ice-cold wash buffer (25 mM Tris-HCl, pH 7.5, 125 mM KCl, and 0.005% Triton X-100, 10% glycerol). Denaturing loading buffer was added to the beads and proteins were subjected to Western immunoblot analysis. PRA1 and PRA2 were detected using anti-HA antibodies (Roche).

Transfection, Subcellular Fractionation, and Immunocytochemistry-- All plasmid constructs were transfected into Chinese hamster ovary (CHO) cells using LipofectAMINE (Life Technologies). CHO cells were seeded at 1 × 105 on 12-mm diameter coverslips overnight and transfected with 0.5 µg of DNA in 1.5 µl of LipofectAMINE. The cells were fixed after 36-48 h in 4% paraformaldehyde (EM Sciences) in phosphate-buffered saline for 30-60 min and washed with 100 mM glycine in phosphate-buffered saline. Cells were incubated with blocking buffer (1% bovine serum albumin, 2% normal goat serum, and 0.4% saponin in phosphate-buffered saline) for 30-60 min at room temperature. Mouse monoclonal anti-HA antibodies (Roche Molecular Biochemicals) were diluted in blocking buffer and incubated with the cells for 1 to 2 h at room temperature. Cells were then washed with 100 mM glycine in phosphate-buffered saline and Alexa 488- or Alexa 568-labeled secondary antibodies (Molecular Probes) were used to detect the bound primary antibodies. Rabbit anti-calnexin (Stressgen) and anti-mannosidase-II (kindly provided by Dr. M. G. Farquhar) were used together with the monoclonal anti-HA in certain cases. Coverlips were mounted with Slow Fade anti-quench solution (Molecular Probes) and confocal laser microscopy (Bio-Rad MRC-1024MP) was used to capture the images. The cells were fixed and stained to visualize the chimeric constructs; however, live cells were imaged for the GFP fusions.

For subcellular fractionation, 100-mm plates of CHO cells were transfected with pIRESpuro/HA-PRA2 in LipofectAMINE. After 24-48 h, the cells were harvested and homogenized in 1 ml of 10 mM Tris-HCl, pH 7.5, 150 mM NaCl (TBS) supplemented with 2 mM phenylmethylsulfonyl fluoride. The crude homogenate was spun at 5,000 × g for 10 min to remove the cell debris, and the resulting supernatant was subjected to centrifugation at 100,000 × g for 1 h to yield the high speed cytosolic and intracellular membrane fractions. To further characterize the membrane-associated PRA2, the high speed membrane fractions were resuspended in 0.1 ml of TBS and extracted with 20 volumes of 0.1 M sodium carbonate, pH 11.5, at 4 °C for 30-60 min. The membranes were then collected by centrifugation at 100,000 × g for 1 h (4 °C). For Triton X-114 extraction, the resuspended membranes were solubilized in 1% Triton X-114 at 4 °C for 30-60 min, and induced to phase partition at 37 °C for 10-15 min followed by centrifugation at 10,000 × g for 5 min at room temperature. The resulting detergent phase was back extracted three times with 10 volumes of ice-cold TBS at 4 °C for 10 min, and phase partitioned as before. The resulting supernatants were pooled and precipitated with 10% trichloroacetic acid.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation and Structural Features of PRA2-- Proteins involved in vesicle transport often exist as multiple isoforms with each mediating specific membrane trafficking steps. A BLAST search of the mouse and rat EST data bases with the conserved region of rat PRA1 revealed a number of overlapping clones. Merging the sequences from two of the longest mouse clones (accession numbers AW519501 and AA051031) revealed an open reading frame of 564 nucleotides. Oligonucleotides spanning the initiation and termination codons were used to PCR amplify rat and mouse brain cDNA libraries. Both gave a PCR product of the expected size, and were subsequently subcloned into a HA-tagged Bluescript vector for DNA sequence analysis. The open reading frame of the rat PRA2 contained 188 amino acids with a predicted molecular mass of 21.5 kDa. As with PRA1, PRA2 also contained two extensive hydrophobic domains, of 36 and 35 residues spanning amino acids 47 to 82 and 101 to 135, respectively. Comparison of the two rat PRA sequences revealed an overall amino acid identity of 26% and a similarity of 35% (Fig. 1). The most conserved domain was located at residues 35 to 47, immediately amino-terminal to the first hydrophobic segment of the two proteins. One notable difference between the two proteins was the length of the amino- and COOH-terminal domains flanking the two hydrophobic segments. PRA2 has a shorter amino-terminal domain of 46 residues compared with 77 in PRA1, but a longer COOH-terminal domain of 53 residues compared with 21 in PRA1. The PRA2 COOH-terminal domain has a cluster of basic residues in contrast to PRA1 which has a number of acidic residues. Moreover, this COOH-terminal domain of PRA2 has a weak coiled-coil conformation, which might play a role in protein-protein interaction. A search of the data base revealed that PRA2 is identical to the rat JWA (accession number AAF60354) and highly similar to the human JM4 (accession number NP 009144) clones.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   PRA2 sequence and comparison to PRA1. The sequences were compared using BestFit alignment program with identical residues indicated by a bar and similar residues with a colon. The predicted hydrophobic domains are underlined.

Northern blot analysis showed that PRA2 was encoded by a single 1.5-1.8-kilobase transcript and broadly expressed in most tissues (Fig. 2). The message was most abundant in the heart and brain. This expression pattern was similar to that of PRA1 (29) with one exception: there was a lower level of expression of PRA2 in the testis whereas PRA1 was highly expressed. This broad expression pattern suggests that PRA2 might also be involved in membrane trafficking events in all tissues. In both PRA1 and PRA2, the testis transcript appeared larger than that from other tissues. The reason for this remained unknown.



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Northern blot analysis of PRA2. Poly(A)+-selected mRNA was probed with the entire coding sequence of PRA2 labeled with 32P. The position of the RNA standards (in kilobase) is indicated on the left.

PRA2 Binds Multiple Rab Isoforms in a Guanine Nucleotide-independent Manner-- Since PRA1 can bind both GDP- and GTP-bound Rab, we examined the interaction of PRA2 with the Rab GTPases. In the yeast two-hybrid system, PRA2 showed a positive beta -galactosidase reaction when tested against the wild-type and GTPase mutant Rab1A and Rab3A (data not shown). As with PRA1, the interaction was abolished when the double Cys prenylation motif of Rab was deleted, suggesting that prenylation is required for interaction. To confirm this interaction, we performed an in vitro binding assay using recombinant Rab1A and Rab3A purified as a 6xHis-tagged fusion protein from the yeast, Saccharomyces cerevisiae, and covalently linked to CNBr-activated Sepharose. The proteins were pre-loaded with GDP, GTP, or maintained in the nucleotide-free state (in the presence of EDTA). Increasing amounts of recombinant HA-tagged PRA1 or PRA2 was added to the beads at 4 °C with the bound proteins recovered and analyzed by Western immunoblot. As shown in Fig. 3A, PRA2 was recovered with the immobilized Rab1A and Rab3A but not with the control Sepahrose beads. There was a slight increase in the amount of PRA2 recovered with immobilized Rab3A compared with Rab1A. PRA2 showed a slightly higher affinity for GTP-bound Rab but was clearly recovered with the GDP-bound as well as guanine nucleotide-free state of both Rab GTPases. Under the same conditions, PRA1 also showed a slight preference for Rab3A over Rab1A (Fig. 3B). There was also a slightly higher affinity for the GTP-bound Rab followed by guanine nucleotide-free and GDP-bound forms. Thus, we conclude that both PRA1 and PRA2 can interact with, at least, Rab1A and Rab3A in the guanine nucleotide-bound and free states.



View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of recombinant PRA1 and PRA2 to Rab1A and Rab3A. A, 40 pmol of immobilized Rab1A (top panel) or Rab3A (bottom panel) was incubated with 10, 15, or 20 pmol of HA-tagged PRA2. The Rab GTPases were preincubated with GTP, GDP, or EDTA, as indicated. Lane C represents the control Sepharose beads incubated with 20 pmol of PRA2. B, the same conditions were used as in panel A except recombinant HA-tagged PRA1 was added to the immobilized Rab. PRA1 and PRA2 bound to the beads were detected with anti-HA antibodies.

PRA2 Is Localized to the ER Compartment-- To determine the cellular distribution, we subcloned the HA-tagged PRA2 into the bicistronic expression vector pIRESpuro, transfected it into CHO cells, and performed a subcellular fractionation analysis. As with PRA1, the protein fractionated with both the high speed supernatant and membranes (Fig. 4). When the membrane fraction was extracted with alkaline carbonate buffer, some of the membrane-bound protein appeared in the soluble fraction similar to the behavior of PRA1 and suggested peripheral association with the membrane. However, the membrane-bound PRA2 partitioned exclusively with the detergent phase when subjected to Triton X-114 extraction and phase separation. In contrast, a significant portion of the membrane-bound PRA1 remained with the aqueous phase in the Triton X-114 extraction. Thus, both PRA1 and PRA2 are highly hydrophobic proteins tightly associated with the membrane but may also appear in the cytosol.



View larger version (70K):
[in this window]
[in a new window]
 
Fig. 4.   Subcellular fractionation and extraction of membrane-bound PRA. Homogenates from CHO transfected with HA-tagged PRA1 (A) and PRA2 (B) were fractionated by centrifugation at 100,000 × g for 1 h. The resulting high speed membrane fractions were further extracted with 0.1 M sodium carbonate, pH 11.5, or with 2% Triton X-114. S and P refer to the supernatant and pellet fractions, respectively. Aq and Det refer to the aqueous and Triton X-114 detergent phases.

When transfected into CHO cells, PRA2 has a striking reticular staining pattern reminiscent of the ER (Fig. 5A). Indeed, there was extensive co-localization with calnexin, a known ER marker. We observed little, if any, co-localization with mannosidase II, a Golgi membrane marker. In contrast, PRA1 was found exclusively associated with the Golgi complex with extensive co-localization with mannosidase II (Fig. 5, C and D). Thus, the two PRA isoforms are localized to distinct intracellular compartments with PRA2 restricted to the ER and PRA1 confined to the Golgi complex (30). This distinct intracellular localization implies that PRA1 and PRA2 may contain targeting signals that direct the protein to the appropriate intracellular compartment. It also implies that each PRA might only interact with a subset of Rab in the cell even though both are capable of binding multiple Rab isoforms in either the GDP- or GTP-bound state.



View larger version (53K):
[in this window]
[in a new window]
 
Fig. 5.   Cellular localization of PRA1 and PRA2. CHO cells were transfected with HA-tagged PRA2 (panels A and B) and PRA1 (panels C and D). The cells were stained with anti-HA (panels A and C), and with either calnexin (panel B) or mannosidase II (panel D) to highlight the ER and Golgi complex, respectively. Scale bar, 2.5 µm.

The Localization Signal Resides in the Carboxyl-terminal Domain of PRA-- To define the organelle-specific targeting signal, we constructed amino-terminal HA-tagged chimeras of PRA1 and PRA2, and determined their cellular localization in transfected CHO cells. Based on the structural features, we divided the two proteins into three separate domains: amino-terminal domain (Domain A), the two hydrophobic segments plus the intervening hydrophilic loop (Domain B), and the charged COOH-terminal domain (Domain C). Hybrid oligonucleotides spanning these domains were used to generate the chimeras by PCR using either HA-tagged PRA1 or PRA2 as the template. As shown in Fig. 6, chimera 1A/2BC, for example, contained Domain A of PRA1 fused to Domains B and C of PRA2. Likewise, chimera 2A/1B/2C contained Domain A of PRA2 fused to Domain B of PRA1 followed by Domain C of PRA2, and so on. The various chimeras were subcloned into the pIRESpuro vector and sequenced to confirm the expected mutations. Two days after transfection, the CHO cells were stained with anti-HA and costained with either anti-mannosidase II or anti-calnexin to identify the Golgi and ER, respectively. As shown in Fig. 7, the COOH-terminal domain of PRA2 targeted the chimera to the ER whether it contained only the amino-terminal Domain A of PRA1 (1A/2BC in Fig. 7A and 6D), both Domains A and B of PRA1 (1AB/2C in Fig. 7, B and E), or only Domain B of PRA1 (2A/1B/2C in Fig. 7, C and F). Similarly, Domain C of PRA1 targeted the chimera to the Golgi complex whether it contained only the amino-terminal Domain A of PRA2 (2A/1BC in Fig. 7, G and J), both Domains A and B of PRA2 (2AB/1C in Fig. 7, H and K), or only Domain B of PRA2 (1A/2B/1C in Fig. 7, I and L). Thus, we concluded that the COOH-terminal domain of PRA1 and PRA2 contained the localization signal that either targeted or caused the protein to be retained at the proper membrane compartment. The amino-terminal Domain A and the two hydrophobic segments in Domain B of the two proteins were interchangeable. For PRA1, its normal localization to the Golgi complex was not altered by the presence of either Domain A (2A/1BC) or Domain B (1A/2B/1C) of PRA2. Likewise, the normal position of PRA2 at the ER was not altered by the presence of either the amino-terminal Domain A (1A/2BC) or Domain B (2A/1B/2C) of PRA1.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Schematic diagram of the PRA1 and PRA2 chimera and their cellular localization. The two proteins were divided into domains A, B, and C. The PRA1 sequence was represented by solid figures and PRA2 sequence by shaded figures. The hydrophobic domains were represented by boxes. Cellular localization was determined based on co-localization with calnexin (ER) and mannosidase II (Golgi).



View larger version (66K):
[in this window]
[in a new window]
 
Fig. 7.   Cellular localization of PRA1 and PRA2 chimeras. The transfected CHO were stained with anti-HA (panels A, C, E, G, I, and K) and with either calnexin (panels B, D, and F) or mannosidase II (panels H, J, and L). The cells were transfected with chimera 1A/2BC (panels A and B), 1AB/2C (panels C and D), 2A/1B/2C (panels E and F), 2A/1BC (panels G and H), 2AB/1C (panels I and J), and 1A/2B/1C (panels K and L).

The Carboxyl-terminal Domain of PRA2 Can Partially Target GFP to the Membrane-- To confirm that the COOH-terminal domain was indeed responsible for targeting the protein to the appropriate membrane compartment, we constructed chimeras containing the full-length or only Domain C of PRA1 and PRA2 fused to the carboxyl terminus of GFP. When transfected into CHO cells, the full-length PRA2 (Fig. 8B) and PRA1 (Fig. 8C) showed a bright fluorescent signal in the ER and Golgi complex, respectively. Thus, the full-length protein was able to direct a cytosolic GFP (Fig. 8A) to a specific membrane organelle. Domain C of PRA2-(132-188) was able to partially target GFP to intracellular membranes where a distinctive punctate staining pattern throughout the cell was clearly evident (Fig. 8D). However, membrane targeting by this domain was inefficient as a significant amount of florescent signal remained in the cytosol. Since this domain of PRA2 contained 57 amino acids, we performed a limited deletion to further define the boundaries of the localization signal. Further deletion of 17 residues in GFP-PRA2-(148-188) or 33 residues in GFP-PRA2-(164-188) completely abrogated this punctate staining pattern (Fig. 8, F and H). Thus, the minimal localization signal must either be contained within the first 17 amino acids immediately COOH-terminal to the second hydrophobic segment or required domains in addition to that contained within Domain C. In contrast to PRA2, GFP fusion of Domain C of PRA1-(162-185), which contained only 24 amino acids, cannot target GFP to intracellular membranes (Fig. 8E). Neither can a further addition of 5 hydrophobic residues in GFP-PRA1-(157-185). When combined with the previous observation, these results suggest that the COOH-terminal domain of PRA2 can partially target proteins to the membrane and that transport of PRA1 to the Golgi complex required additional domains such as ones that can functionally interact with Rab or VAMP2.



View larger version (52K):
[in this window]
[in a new window]
 
Fig. 8.   GFP chimeras of PRA1 and PRA2. The native GFP showed an even cytosolic pattern in transfected CHO (panel A) while a GFP fusion with the full-length PRA2 (panel B) and PRA1 (panel C) targeted the protein to the ER and Golgi, respectively. Representative of the GFP-PRA1 chimeras, GFP-PRA1-(162-185) and GFP-PRA1-(157-185) were shown in panels E and G, respectively. Representative of GFP-PRA2-(132-188) was shown in panel D, GFP-PRA2-(148-188) in panel F, and GFP-PRA2-(164-188) in panel H.

Charged Residues at the Carboxy Terminus Direct Organelle-specific Targeting of PRA-- One striking feature of the COOH-terminal domain of the PRA isoforms is their overall charge. PRA1 contained a number of acidic residues whereas the first 15 amino acids of Domain C in PRA2 contained numerous basic residues. The carboxyl terminus of PRA1 contained an additional glutamate immediately after the consensus DXE motif (residues 176-178) involved in the exit of membrane proteins from the ER (35, 36). To test whether this DXEE motif might constitute the sorting signal of PRA1, we mutated these residues to alanine or to basic residues and examined their effect on cellular localization. Targeting of PRA1 to the Golgi complex was lost when either one of the acidic residues (Asp176, Glu178, or Glu179), both glutamate residues (Glu178 and Glu179), and all three acidic residues within the DXEE motif were changed to alanine (Fig. 9A). It is noteworthy that mutation of the Glu179 residue alone while leaving an intact DXE motif also abolished localization to the Golgi complex. Mutation of all three acidic residues to lysine also caused mislocalization to the ER. These results indicate that the DXEE motif is essential for effective Golgi localization of PRA1, and the additional glutamate residue is indispensable for exit from the ER compartment.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of mutation of PRA1 and PRA2 on cellular localization. A, mutations introduced to COOH-terminal residues of PRA1 and their resulting cellular localization. B, mutations introduced to the COOH-terminal basic residues of PRA2 and their resulting cellular localization.

Since the COOH-terminal domain of PRA2 can partially direct GFP to intracellular membranes and contained a number of basic residues, we decided to perform a mutagenic analysis of this region. The presence of basic amino acids immediately following a transmembrane domain on the cytoplasmic side of cytochrome P-450 has been shown to exclude the protein from ER transport vesicles (37). However, we observed no alteration in the ER localization of PRA2 when the basic residues within the first 15 amino acids (Arg140, Arg142, Lys145, and Lys147) were changed to alanine (AAAA in Fig. 9B). Changing the basic residues Arg140, Arg142, Lys145, Lys147, and Lys151 to glutamate (acidic in Fig. 9B) resulted in partial localization to the Golgi complex. This might be due to introduction of a di-acidic motif that mimicked a DXE motif. If so, this suggests that the protein may exit the ER but is subsequently retrieved. Retrieval of membrane proteins has been shown to depend on a di-basic KKXX motif located at the COOH-terminal end (38, 39). Since PRA2 does not contain this KKXX motif, we explored the possibility that the basic residues located at the COOH-terminal end, KARE, might mimic this ER retrieval signal. Mutation of Lys185 or Arg187 to alanine resulted in partial localization to the Golgi complex. Similarly, introduction of either K185A or R187A in the context of a PRA2 with an acidic COOH-terminal domain resulted in predominantly Golgi localization (acidic/K185A and acidic/R187A in Fig. 9B). Thus, our results indicate that PRA2 can be transported to the Golgi complex despite the lack of a di-acidic motif for exit from the ER. But the protein is efficiently retrieved from the pre-Golgi compartment through a process that partially depended on a KXRX motif at the extreme carboxyl terminus.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteins involved in vesicle transport are conserved throughout evolution with specific members of each protein family mediating similar functions at each step of the secretory pathway. We have isolated a second PRA isoform from a rat brain cDNA library based on sequence similarity to a conserved domain in PRA1. Northern analysis showed that PRA2 is ubiquitously expressed in all tissues, suggesting that it might also participate in general membrane trafficking events. Although the overall identity of the two proteins is relatively low, we concluded that the two proteins belong to the same family based on their overall structural similarity and ability to bind to Rab. PRA2 also contains two extensive hydrophobic domains (36 and 35 residues). Subcellular fractionation analysis indicates that the two proteins share properties of both cytosolic and membrane proteins. A significant portion of the two proteins fractionated with the high speed supernatant. The membrane-bound PRA2 behaved as an integral membrane protein in that it partitioned with the Triton X-114 detergent phase. However, a fraction of the membrane-bound PRA2 can be extracted with alkaline carbonate buffer. In the case of PRA1, a portion of the membrane-bound protein was extracted with alkaline carbonate buffer and partitioned with the aqueous phase when extracted with Triton X-114. These properties suggest that PRA might be partially embedded in the lipid bilayer. A more compelling argument that PRA2 is an isoform of the PRA family is its ability to bind, at least, Rab1A and Rab3A in an in vitro binding assay. The binding property was very similar to PRA1 in that both proteins can bind Rab1A and Rab3A in GDP-, GTP-, and guanine nucleotide-free states. This is similar to that of Mss4, a cytosolic protein that can bind to the transient guanine nucleotide-free state of Rab (40). However, the interaction differs with respect to the prenylation state of Rab. Binding of Rab to PRA1 and PRA2 is highly dependent on prenylation as deletion of the double cysteine-motif completely abrogated protein-protein interaction in the yeast two-hybrid system (not shown). In contrast, Mss4 can interact with the lipid-unmodified form of Rab (41). Since PRA1 can bind specifically to VAMP2, we also tested whether PRA2 could interact with some of the VAMP isoforms. We were unable to detect any interaction between PRA2 and VAMP1, VAMP2, or VAMP3 (cellubrevin) in the yeast two-hybrid system and in vitro binding assays (not shown). Thus, we can exclude VAMP1-3 as possible PRA2-interacting proteins.

Most studies on protein localization within the secretory pathway focused on sorting and transport of cargo or integral membrane proteins. These proteins enter the secretory pathway by insertion into or translocation across the ER membrane. The selection thereafter for transport, retention, or retrieval depends on specific interaction of localization signals present in the protein with the transport machinery. Similarly, proteins localized entirely on the cytoplasmic side of the membrane contain signals mediating specific targeting to an organelle. For example, a FYVE finger domain is essential in mediating specific localization of EEA1 to endosomes (42), a GRIP domain in targeting to the Golgi complex (43) or a GRASP65-binding site for Golgi localization of GM130 (26). The two PRA isoforms do not contain any of these domains, but have very distinct intracellular localization. We have determined that the sorting signal lies within the carboxyl terminus following the second hydrophobic domain. This domain clearly determines the intracellular localization such that replacing the PRA1 COOH-terminal domain with that from PRA2 targeted the chimera to the ER, the normal cellular localization of PRA2. Likewise, replacing the PRA2 COOH-terminal domain with that from PRA1 resulted in targeting of the chimera to the Golgi complex, the normal localization of PRA1. The importance of this domain was also evident in our previous observation where its deletion resulted in insertion of PRA1 into the ER membrane (30). For PRA2, this COOH-terminal domain was able to partially target the cytosolic GFP to the membrane, suggesting that it is capable of interacting with ER-specific transport machinery. However, efficient targeting may require an additional domain or perhaps functional interaction with Rab. This may also apply to PRA1 since the COOH-terminal domain alone or together with five upstream hydrophobic amino acids was not able to direct membrane association of GFP. However, when fused to upstream PRA2 domains, it could target the protein to the Golgi membrane.

Since PRA shared properties of integral membrane proteins, we examined whether sorting signals for membrane proteins might be responsible for PRA-specific targeting. Efficient export of vesicular stomatitis virus G glycoprotein from the ER requires a di-acidic DXE motif (35, 36) found on the COOH-terminal side of a YXXphi motif (where phi  is a hydrophobic residue) at the cytoplasmic side of the membrane (44). The carboxyl terminus of PRA1 is overall acidic in nature but contains a DXEE motif (residues 176 to 179). However, this COOH-terminal domain alone was insufficient in targeting the cytosolic GFP reporter protein to the Golgi or any intracellular membrane. In the context of a full-length PRA1, the DXE motif is essential in Golgi localization and mutation of Asp176 or Glu178 resulted in retention in the ER. Interestingly, mutation of Glu179, which contains an intact DXE motif, also resulted in loss of Golgi localization. Thus, efficient Golgi localization of PRA1 required an additional glutamate beside the DXE motif, and our results suggest that PRA1 might be associated with the transport machinery utilized by membrane proteins to exit from the ER.

Localization of membrane proteins in the ER may result from exclusion from ER transport vesicle or retrieval from the pre-Golgi compartment. In certain cases, a transmembrane domain with basic amino acids immediately following it on the cytoplasmic side may serve to exclude the protein from ER transport vesicles (37). We explored the possibility that the basic residues following the second hydrophobic domain might mimic this motif thereby allowing PRA2 to remain in the ER. However, mutagenesis of these basic residues to alanine showed no effect on PRA2 localization. Retention of membrane proteins in the ER can also result from protein retrieval from the pre-Golgi compartment, a process that requires a di-basic KKXX motif at the cytoplasmic tail (38, 39, 45). PRA2 does not contain a KKXX motif at the carboxyl terminus, but ends with KARE (residues 185 to 188) that might mimic this retrieval signal. We found that mutation of either one of the basic residues resulted in partial localization to the Golgi complex. This suggests that the protein normally transits from the ER to the Golgi complex, and that mutation of the terminal basic residues resulted in reduced retrieval from the Golgi complex. It is interesting to note that PRA2 does not contain a DXE motif at the COOH-terminal domain, yet is capable of transport to the Golgi complex. Moreover, transport to the Golgi complex can be enhanced by the creation of a di-acidic motif at the COOH-terminal domain.

Our data suggest that PRA1 enters the secretory pathway at the ER compartment and is efficiently transported to the Golgi complex through its DXEE motif at the carboxyl terminus. It can progress beyond the Golgi complex since PRA1 was detectable on synaptic vesicle membrane (46). PRA2 also enters the secretory pathway at the ER compartment and is transported to the Golgi complex independent of a DXE motif. It is then retrieved, possibly through its KXRX motif and returned to the ER compartment. Thus, intracellular localization of PRA is likely due to its interaction with the same machinery that sorts proteins for export out of the ER and retrieval from the pre-Golgi compartment. This might serve to recruit or retain Rab on the transport vesicles. Despite the broad specificity for Rab, the distinct cellular localization of PRA implies that each isoform may be restricted in its interaction to a subset of Rab.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 613-798-5555 (ext. 17079); Fax: 613-761-5365; E-mail: jngsee@lri.ca

Published, JBC Papers in Press, November 28, 2000, DOI 10.1074/jbc.M009073200


    ABBREVIATIONS

The abbreviations used are: ER, endoplasmic reticulum; PRA, prenylated Rab acceptor; HA, hemagglutinin; PCR, polymerase chain reaction; GTPbeta S, guanyl-5'-yl thiophosphate; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; GDPbeta S, guanyl-5'-yl thiophosphate; CHO, Chinese hamster ovary.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Chavrier, P., Vingron, M., Sander, C., Simons, K., and Zerial, M. (1990) Mol. Cell. Biol. 10, 6578-6585[Medline] [Order article via Infotrieve]
2. Elferink, L. A., Anzai, K., and Scheller, R. H. (1992) J. Biol. Chem. 267, 5768-5775[Abstract/Free Full Text]
3. Ngsee, J. K., Elferink, L. A., and Scheller, R. H. (1991) J. Biol. Chem. 266, 2675-2680[Abstract/Free Full Text]
4. Matteoli, M., Takei, K., Cameron, R., Hurlbut, P., Johnston, P. A., Sudhof, T. C., Jahn, R., and De Camilli, P. (1991) J. Cell Biol. 115, 625-633[Abstract]
5. Fischer von Mollard, G., Mignery, G. A., Baumert, M., Perin, M. S., Hanson, T. J., Burger, P. M., Jahn, R., and Sudhof, T. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1988-1992[Abstract]
6. Zahraoui, A., Touchot, N., Chardin, P., and Tavitian, A. (1988) Nucleic Acids Res. 16, 1204[Medline] [Order article via Infotrieve]
7. Van Der Sluijs, P., Hull, M., Zahraoui, A., Tavitian, A., Goud, B., and Mellman, I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6313-6317[Abstract]
8. Andres, D. A., Seabra, M. C., Brown, M. S., Armstrong, S. A., Smeland, T. E., Cremers, F. P., and Goldstein, J. L. (1993) Cell 73, 1091-1099[Medline] [Order article via Infotrieve]
9. Johnston, P. A., Archer, B. D., Robinson, K., Mignery, G. A., Jahn, R., and Sudhof, T. C. (1991) Neuron 7, 101-109[Medline] [Order article via Infotrieve]
10. Khosravi-Far, R., Lutz, R. J., Cox, A. D., Conroy, L., Bourne, J. R., Sinensky, M., Balch, W. E., Buss, J. E., and Der, C. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6264-6268[Abstract]
11. Khosravi-Far, R., Clark, G. J., Abe, K., Cox, A. D., McLain, T., Lutz, R. J., Sinensky, M., and Der, C. J. (1992) J. Biol. Chem. 267, 24363-24368[Abstract/Free Full Text]
12. Kinsella, B. T., and Maltese, W. A. (1992) J. Biol. Chem. 267, 3940-3945[Abstract/Free Full Text]
13. Wei, C., Lutz, R., Sinensky, M., and Macara, I. G. (1992) Oncogene 7, 467-473[Medline] [Order article via Infotrieve]
14. Wada, M., Nakanishi, H., Satoh, A., Hirano, H., Obaishi, H., Matsuura, Y., and Takai, Y. (1997) J. Biol. Chem. 272, 3875-3878[Abstract/Free Full Text]
15. Walch-Solimena, C., Collins, R. N., and Novick, P. J. (1997) J. Cell Biol. 137, 1495-1509[Abstract/Free Full Text]
16. Elkind, N. B., Walch-Solimena, C., and Novick, P. J. (2000) J. Cell Biol. 149, 95-110[Abstract/Free Full Text]
17. Fukui, K., Sasaki, T., Imazumi, K., Matsuura, Y., Nakanishi, H., and Takai, Y. (1997) J. Biol. Chem. 272, 4655-4658[Abstract/Free Full Text]
18. Albert, S., and Gallwitz, D. (1999) J. Biol. Chem. 274, 33186-33189[Abstract/Free Full Text]
19. Strom, M., Vollmer, P., Tan, T. J., and Gallwitz, D. (1993) Nature 361, 736-739[CrossRef][Medline] [Order article via Infotrieve]
20. Cao, X., Ballew, N., and Barlowe, C. (1998) EMBO J. 17, 2156-2165[Abstract/Free Full Text]
21. Cao, X., and Barlowe, C. (2000) J. Cell Biol. 149, 55-66[Abstract/Free Full Text]
22. Brigance, W. T., Barlowe, C., and Graham, T. R. (2000) Mol. Biol. Cell 11, 171-182[Abstract/Free Full Text]
23. VanRheenen, S. M., Cao, X., Sapperstein, S. K., Chiang, E. C., Lupashin, V. V., Barlowe, C., and Waters, M. G. (1999) J. Cell Biol. 147, 729-742[Abstract/Free Full Text]
24. Sacher, M., Jiang, Y., Barrowman, J., Scarpa, A., Burston, J., Zhang, L., Schieltz, D., Yates, J. R., 3rd, Abeliovich, H., and Ferro-Novick, S. (1998) EMBO J. 17, 2494-2503[Abstract/Free Full Text]
25. Christoforidis, S., McBride, H. M., Burgoyne, R. D., and Zerial, M. (1999) Nature 397, 621-625[CrossRef][Medline] [Order article via Infotrieve]
26. Barr, F. A., Nakamura, N., and Warren, G. (1998) EMBO J. 17, 3258-3268[Abstract/Free Full Text]
27. Guo, W., Roth, D., Walch-Solimena, C., and Novick, P. (1999) EMBO J. 18, 1071-1080[Abstract/Free Full Text]
28. Murthy, V. N., and Stevens, C. F. (1999) Nat. Neurosci. 2, 503-507[CrossRef][Medline] [Order article via Infotrieve]
29. Martincic, I., Peralta, M. E., and Ngsee, J. K. (1997) J. Biol. Chem. 272, 26991-26998[Abstract/Free Full Text]
30. Hutt, D. M., Da-Silva, L. F., Chang, L. H., Prosser, D. C., and Ngsee, J. K. (2000) J. Biol. Chem. 275, 18511-18519[Abstract/Free Full Text]
31. Advani, R. J., Bae, H. R., Bock, J. B., Chao, D. S., Doung, Y. C., Prekeris, R., Yoo, J. S., and Scheller, R. H. (1998) J. Biol. Chem. 273, 10317-10324[Abstract/Free Full Text]
32. Advani, R. J., Yang, B., Prekeris, R., Lee, K. C., Klumperman, J., and Scheller, R. H. (1999) J. Cell Biol. 146, 765-776[Abstract/Free Full Text]
33. Zeng, Q., Subramaniam, V. N., Wong, S. H., Tang, B. L., Parton, R. G., Rea, S., James, D. E., and Hong, W. (1998) Mol. Biol. Cell 9, 2423-2437[Abstract/Free Full Text]
34. Gietz, R. D., Schiestl, R. H., Willems, A. R., and Woods, R. A. (1995) Yeast 11, 355-360[Medline] [Order article via Infotrieve]
35. Nishimura, N., and Balch, W. E. (1997) Science 277, 556-558[Abstract/Free Full Text]
36. Nishimura, N., Bannykh, S., Slabough, S., Matteson, J., Altschuler, Y., Hahn, K., and Balch, W. E. (1999) J. Biol. Chem. 274, 15937-15946[Abstract/Free Full Text]
37. Szczesna-Skorupa, E., and Kemper, B. (2000) J. Biol. Chem. 275, 19409-19415[Abstract/Free Full Text]
38. Jackson, M. R., Nilsson, T., and Peterson, P. A. (1993) J. Cell Biol. 121, 317-333[Abstract]
39. Jackson, M. R., Nilsson, T., and Peterson, P. A. (1990) EMBO J. 9, 3153-3162[Abstract]
40. Nuoffer, C., Wu, S. K., Dascher, C., and Balch, W. E. (1997) Mol. Biol. Cell 8, 1305-1316[Abstract]
41. Miyazaki, A., Sasaki, T., Araki, K., Ueno, N., Imazumi, K., Nagano, F., Takahashi, K., and Takai, Y. (1994) FEBS Lett. 350, 333-336[CrossRef][Medline] [Order article via Infotrieve]
42. Stenmark, H., Aasland, R., Toh, B. H., and D'Arrigo, A. (1996) J. Biol. Chem. 271, 24048-24054[Abstract/Free Full Text]
43. Munro, S., and Nichols, B. J. (1999) Curr. Biol. 9, 377-380[CrossRef][Medline] [Order article via Infotrieve]
44. Sevier, C. S., Weisz, O. A., Davis, M., and Machamer, C. E. (2000) Mol. Biol. Cell 11, 13-22[Abstract/Free Full Text]
45. Schutze, M. P., Peterson, P. A., and Jackson, M. R. (1994) EMBO J. 13, 1696-1705[Abstract]
46. Fenster, S. D., Chung, W. J., Zhai, R., Cases-Langhoff, C., Voss, B., Garner, A. M., Kaempf, U., Kindler, S., Gundelfinger, E. D., and Garner, C. C. (2000) Neuron 25, 203-214[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.